METASTATIC MELANOMA

This study is testing whether a short course of two targeted cancer drugs (trametinib and dabrafenib), given alongside an immunotherapy drug (pembrolizumab), works better than expected for people with advanced melanoma that cannot be removed by surgery. The goal is to see if this…

This early-stage trial is testing a new way to give an immunotherapy drug called nivolumab to patients with melanoma or lung cancer that has spread to the membranes surrounding the brain and spinal cord. The goal is to see if giving the drug directly into the spinal fluid, along …

This study is testing a highly focused, single-dose radiation treatment for people with melanoma that has spread to more than three spots in the brain. The main goals are to see if this treatment can control the brain tumors and, importantly, if it causes less memory and thinking…

This early-stage study is testing the safety and best dose of a new drug combination for advanced melanoma that has spread or cannot be surgically removed. It combines pembrolizumab, an immunotherapy drug, with ibrutinib, a drug that may block cancer cell growth. The goal is to s…

This study is testing whether a pill called ibrutinib can help control advanced skin melanoma that has continued to grow despite standard immunotherapies and other targeted drugs. It involves 18 patients with stage IV melanoma who take the pill daily. The main goal is to see if t…

This early-stage study is testing a personalized cell therapy called lifileucel for patients whose melanoma has spread to the brain and is no longer responding to standard immunotherapy. Doctors will collect a patient's own tumor-fighting immune cells, grow them in a lab, and inf…

This early-stage clinical trial is testing a new experimental drug called RO7247669 in people with advanced solid tumors that have spread. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it might help shrink tumors. The …

This early-stage study is testing a new combination treatment for advanced melanoma that has not responded to other therapies. It uses a modified virus designed to infect and kill cancer cells, combined with the patient's own tumor-fighting immune cells and a short course of chem…

This study tested whether adding a drug called GM-CSF (sargramostim) to an existing immune-boosting cancer drug (ipilimumab) could help patients with advanced melanoma live longer. The trial involved 245 adults whose melanoma could not be removed by surgery. Researchers compared …

This early-stage trial is testing the safety of a new combination treatment for people with advanced cancers that have spread and cannot be removed by surgery. Doctors inject immune-stimulating drugs directly into a tumor, then give a small dose of radiation to that same spot. Th…

This early-stage study aimed to test the safety and early effectiveness of a personalized cell therapy called STIL101. The therapy involved growing a patient's own cancer-fighting immune cells (T-cells) from a tumor sample in a lab and then infusing them back. It was designed for…

This study is testing whether using two treatments together works better than one to control cancer that has spread to the spine and is at risk of pressing on the spinal cord. Doctors combine a heat treatment (thermal ablation) that destroys tumor cells with a very precise, high-…

This study is for people with advanced melanoma that has a specific BRAF gene mutation and cannot be removed by surgery. It is testing which order of two powerful treatment combinations leads to longer survival. One group starts with immunotherapy (ipilimumab + nivolumab) and swi…

This study is testing two different combinations of three drugs to see if they are safe and effective for people with advanced melanoma that has a specific genetic change (BRAF mutation) and has spread or cannot be removed by surgery. The goal is to control the cancer by using an…

This study is testing a new three-drug combination to see if it works better than the current two-drug standard for treating advanced melanoma with a specific BRAF gene mutation. The trial aims to find the safest dose and see if adding a third drug (navitoclax) helps shrink tumor…

This early-stage study is testing whether a personalized vaccine made from a patient's own tumor can be safely combined with other immune-boosting drugs to treat melanoma. The vaccine, called NeoVax, is designed to teach the body's immune system to recognize and attack cancer cel…

This study is testing if adding a drug called infliximab to standard immunotherapy helps people with advanced melanoma. The goal is to see if this combination can better control the cancer while also reducing the severe digestive side effects that immunotherapy sometimes causes. …

This early-stage study is testing a new drug called ST101 in patients with advanced solid tumors that cannot be surgically removed and have spread. The trial aims to find a safe and effective dose for cancers including glioblastoma, melanoma, breast cancer, and prostate cancer in…

This early-stage study is testing a new combination of two drugs, sonidegib and pembrolizumab, for people with advanced solid tumors that have spread. The main goals are to find the safest dose of the combination and see if it helps shrink or control the cancer. The study is enro…

This early-phase study is testing a combination of immunotherapy drugs (nivolumab and ipilimumab) along with standard transplant medications (tacrolimus and prednisone) in kidney transplant patients with advanced skin cancers that have spread or cannot be removed by surgery. The …

This is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…

This early-stage study is testing a combination of two oral drugs, cediranib and selumetinib, in patients with advanced solid tumors that cannot be removed by surgery and have no standard treatment options. The main goals are to find the safest dose and understand the side effect…

This study is testing a new three-drug combination for people with advanced melanoma that has a specific genetic change (BRAF mutation) and has gotten worse despite standard targeted therapy. The goal is to see if adding a drug called tazemetostat to two existing drugs (dabrafeni…

This study is testing whether combining the drugs Avastin and Tencentriq, with or without a third drug called Cotellic, can help control melanoma that has spread to the brain. It is for adults with this specific type of advanced skin cancer who have not yet received treatment for…

This early-stage study is testing a new combination of two existing cancer drugs, pembrolizumab and ziv-aflibercept, in patients with advanced solid tumors. The main goal is to find the safest and most effective dose of the combination. Researchers will also look for early signs …

This study is testing whether eating a high-fiber diet can improve gut health and help the immune system fight cancer in patients with advanced melanoma who are receiving standard immunotherapy. Fifty participants will be randomly assigned to follow either a high-fiber diet or a …

This is a first-in-human study to test the safety and find the right dose of a new, personalized cell therapy called OBX-115, given with the drug acetazolamide. It is for adults whose metastatic melanoma has come back or stopped responding to standard immunotherapy. Researchers w…

This study aimed to test the safety and effectiveness of a portable electrical device (NovoTTF-200A) when used together with the immunotherapy drug pembrolizumab for people with melanoma that had spread to the brain. The device, worn like a backpack, delivers low-intensity electr…

This study is testing a new combination treatment for people with advanced lung cancer, melanoma, kidney cancer, or head and neck cancer that has stopped responding to standard immunotherapy. The treatment involves three parts: a targeted radiation dose to one tumor, injections o…

This early-stage study is testing a personalized treatment called TBio-4101 for people with advanced melanoma that hasn't responded to standard therapies. Doctors take immune cells from a patient's tumor, grow them in large numbers in a lab, and then infuse them back into the pat…

This early-stage study is testing the safety of a new personalized treatment for advanced melanoma. Doctors take a patient's own immune cells, genetically modify them in a lab to better recognize and attack cancer, and then infuse them back into the body. The goal is to see if th…

This study is testing a combination of three immunotherapy drugs—tocilizumab, ipilimumab, and nivolumab—in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. The main goal is to see if adding tocilizumab can help manage the serious side effects someti…

This early-stage study is testing an inhaled form of an immune-boosting drug (aldesleukin) for people whose cancer has spread to their lungs. The main goals are to find a safe dose and see if the treatment causes side effects. Researchers also want to learn if inhaling the drug d…

This study is testing whether adding an experimental pill called GSK2636771 to an approved immunotherapy drug (pembrolizumab) can help control advanced melanoma that has not responded to prior treatment and has a specific genetic feature called PTEN loss. The main goals are to fi…

This study is testing whether adding an oral drug called azacitidine to the immunotherapy pembrolizumab can help control advanced melanoma. It is for patients who are new to this type of immunotherapy or whose cancer has worsened despite it. The main goal is to see if the combina…